VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGIO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGIOAgios Pharmaceuticals, Inc.
$29.89$1.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
AGIO logo

Agios Pharmaceuticals, Inc.

AGIO
NASDAQ · Rare Disease Biotech
$29.89
At close - Nov 17, 4:00 PM EST - USD
Market Cap$1.78B
P/E-4.8x
52W High$46.00
Volume630.57K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Ramp Versus Persistent Cash Burn at AGIO

AGIO's revenue has climbed from $8.6M in 2024Q2 to $55.4M in 2026Q3 and gross margin has expanded to 95.4%, suggesting the PYRUKYND launch is gaining commercial traction.

GrowthExpanding
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

AGIO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

-111% Peers

P/E is 111% below peer median

03

Market leadership

RS 49 · Lag

Laggard (Underperforming 51% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
AGIO+9.97%
S&P 500 (^GSPC)+7.21%
1-Year Return
AGIO-33.77%
S&P 500 (^GSPC)+10.03%
3-Year Return
AGIO+34.28%
S&P 500 (^GSPC)+61.02%
5-Year Return
AGIO-24.65%
S&P 500 (^GSPC)+58.73%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-4.8x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-4.8x
2.8x
0th· Low
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$4.76-84.1%
Base (Fair)$26.37-16.5%
Bull$7.84-73.8%
$4.76 Bear$26.37 Base$7.84 Bull
Current Market Price: $29.89
Trades at a 13.3% premium to Base DCF ($26.37)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$54M+48.0% YoY
Net income FY25
-$413M-161.3% YoY
Free cash flow FY25
-$377M+3.6% YoY
Operating margin FY25
-873.9%+292.6 pts YoY
ROIC (FY25)-26.6%
Avg ROIC 5Y-29.7%
ROE (TTM)-34.6%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$1.09+12.1%
vs -$1.24
$55M+7.2%
vs $52M
Q3 2026
Jul 30, 2026
-$1.69-2.4%
vs -$1.65
$45M+69.5%
vs $26M
Q2 2026
Apr 29, 2026
-$1.69+6.6%
vs -$1.81
$21M+56.0%
vs $13M
Q1 2026
Feb 12, 2026
-$1.85+6.1%
vs -$1.97
$20M+65.1%
vs $12M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·Nov 7, 2026
Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript

Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Alec Stranahan - BofA Securities, Research Division Samantha Semenkow - Citigroup Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Anish Nikhanj - Truist Securities, Inc., Research Division Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Joseph Thome - TD Cowen, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Luca Issi - RBC Capital Markets, Research Division Presentation Operator Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2026 Conference Call.

MarketBeat·Nov 5, 2026
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

Agios Pharmaceuticals NASDAQ: AGIO reported record third-quarter product revenue as its thalassemia drug AQVESME continued its U.S. launch, while the company prepares for a delayed regulatory decision on the drug's use in sickle cell disease.

Zacks Investment Research·Nov 5, 2026
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.78 per share a year ago.

GlobeNewsWire·Nov 5, 2026
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in thalassemia continues, with 619 cumulative prescriptions with completed start forms from REMS-certified physicians, plus 48 additional prescriptions with start forms in process as of September 30, 2026 New PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA 14 abstracts accepted at ASH 2026, including new clinical data for mitapivat in sickle cell disease and for AG-236 in polycythemia vera, highlighting the breadth and depth of Agios' rare hematology portfolio $907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028 CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026.

Filtered for Agios Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark AGIO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Agios Pharmaceuticals, Inc. (AGIO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
AGIO logoAGIOAgios Pharmaceuticals, Inc.Current
$29.89$1.78B-4.7948.03%-264.76%-34.63%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$26.96$4.48B-8.2033.87%-56.9%-120.44%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.36$5.01B-47.55114.51%-9.17%——
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.70$1.64B-3.2520.13%-71.78%——
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
RYTM logoRYTMRhythm Pharmaceuticals, Inc.
$116.61$8B-41.5445.83%-69.03%-83.68%—

Compare AGIO vs Peers

Agios Pharmaceuticals, Inc. (AGIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IONS

Most directly comparable listed peer for AGIO.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare AGIO against a more recognizable public peer.

Peer Set

Compare Top 5

vs IONS, PTCT, RARE, IMVT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AGIO SEC Filings & Documents

Agios Pharmaceuticals, Inc. (AGIO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Jul 30, 2026·SEC

Material company update

Jun 18, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 12, 2026·SEC

FY 2025

Feb 13, 2025·SEC

FY 2024

Feb 15, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Jul 30, 2026·SEC

FY 2026

Apr 29, 2026·SEC

Get notified when AGIO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

AGIO Frequently Asked Questions

Agios Pharmaceuticals, Inc. (AGIO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Agios Pharmaceuticals, Inc.'s revenue?

Agios Pharmaceuticals, Inc. (AGIO) reported $140.8M in revenue over the trailing twelve months. Revenue was $54.0M in fiscal year 2025. That is 147% more than the $21.8M of fiscal year 2011.

How fast is Agios Pharmaceuticals, Inc. growing?

Agios Pharmaceuticals, Inc. (AGIO) grew revenue by 214.4% over the trailing twelve months, compared with the twelve months before.

Is AGIO profitable?

No. Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $372.9M over the trailing twelve months.

Dividend & Returns
What is AGIO's return on equity?

Agios Pharmaceuticals, Inc. (AGIO) had a return on equity (ROE) of -34.6% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Agios Pharmaceuticals, Inc.'s free cash flow?

Agios Pharmaceuticals, Inc. (AGIO) had negative free cash flow of $336.0M over the trailing twelve months.

What if you invested $1,000 in AGIO back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →